Axon Seminar In Vitro Diagnostics Wednesday 12 September 2012

Bringing an in vitro diagnostic product to the market is challenging and complex. Rules at the EU and national level are constantly changing, while regulatory policy is developing to get to grips with new products. A robust and scientifically supported regulatory and legal strategy is therefore key to successful market access.

Speakers and their presentations:

Sabine Ohse, Head Medical Devices Certification at BSI Group Regulatory strategy for in vitro diagnostics in the EU

Henk Vietor, CEO at Skyline Diagnostics Company experience with regulatory issues and how to deal with them

Erik Vollebregt, Partner at Axon Lawyers IVD Capita Exotica

Carine van den Brink, Partner at Axon Lawyers Promotion and sale of IVDs in EU


Navigate through our knowledgebase

Related articles

Article

Verelendung is a process, people!

Over the summer holidays I (and perhaps some other people too) were in burning anticipation about announced measures to be adopted to deal with the MDR slowly moving to a big crunch…

Read more

Article

The Blue Guide 2022 update – new elements regarding applicability of EU law on products

As announced in my previous blog post providing a general overview of my impression of the changes made in the Blue Guide 2022 compared to the previous 2016 version, this blog post…

Read more

Article

The Blue Guide 2022 update – new elements regarding applicability of EU law on products

As announced in my previous blog post providing a general overview of my impression of the changes made in the Blue Guide 2022 compared to the previous 2016 version, this blog post follows up in detail on the changes in Chapter 2. Chapter 2 of the Blue Guide explains when EU law on products applies, […]